Please login to the form below

Not currently logged in
Email:
Password:

BenevolentAI appoints new head of cheminformatics

Dr Nathan Brown joins from the Institute of Cancer Research

Artificial Intelligence (AI) group BenevolentAI has appointed Dr Nathan Brown as its new head of cheminformatics.

Brown joins the group from the Institute of Cancer Research (ICR), where he founded and led the new In Silico Medicinal Chemistry Group, which focussed on medicinal chemistry research towards novel cancer treatments.

He also has experience as a software designer and has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology.

Jackie Hunter, CEO of BenevolentBio, the bioscience subsidiary of BenevolentAI, said: “Nathan is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.

“He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published. We are delighted to have him on board.”

Brown succeeds Mark Davies who has been promoted to vice president, Biomedical Informatics.

1st August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics